Viridian Therapeutics, Inc. (VRDN)

In October 2025, Viridian Therapeutics announced and priced an underwritten public offering of 11,425,000 shares of its common stock at $22.00 per share, aiming to raise approximately $251.35 million. In October 2025, Viridian secured a royalty financing agreement with DRI Healthcare Acquisitions LP for up to $300 million. Positive topline data for veligrotug from THRIVE and THRIVE-2 Phase 3 trials were reported in late 2024 and highlighted in early 2025. Completion of enrollment in the REVEAL-1 and REVEAL-2 Phase 3 clinical trials for VRDN-003 was announced in September 2025. Proof-of-concept IgG reduction clinical data for VRDN-006 in healthy volunteers was anticipated in Q3 2025, and an IND submission for VRDN-008 is on track for year-end 2025. Analyst sentiment has been moderately to overwhelmingly positive, and Veligrotug received Breakthrough Therapy Designation from the FDA in May 2025. Viridian entered an exclusive licensing agreement with Kissei Pharmaceutical for the development of its treatments in Japan.

There is strong patient demand for Viridian Therapeutics' thyroid eye disease treatments, as evidenced by the company exceeding enrollment targets in its THRIVE and REVEAL clinical trials. However, the provided information does not indicate any specific seasonality in the demand for Viridian Therapeutics' products or services.

Viridian Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing medicines for serious and rare diseases, particularly Thyroid Eye Disease (TED). The company is dedicated to discovering and developing potential best-in-class therapies for patients with serious and underserved autoimmune diseases, with a primary focus on TED. Veligrotug is an intravenously administered humanized monoclonal antibody targeting IGF-1R for the treatment of TED, and a BLA submission is anticipated in November 2025, with a potential commercial launch in mid-2026 if approved under Priority Review. VRDN-003 is a subcutaneous (SC) insulin-like growth factor-1 receptor (IGF-1R) antibody, designed for convenient, low-volume, self-administered injections, with topline data expected in the first half of 2026 and a BLA submission planned by year-end 2026. VRDN-006 and VRDN-008 are a portfolio of engineered neonatal Fc receptor (FcRn) inhibitors, with VRDN-006 demonstrating IgG reduction in healthy volunteers and VRDN-008 having an IND submission on track for year-end 2025.

Viridian Therapeutics, Inc. is based in Waltham, Massachusetts. The company conducts global Phase 3 clinical trials for its lead product candidates, indicating an international reach in its development activities.

Viridian Therapeutics maintains a positive reputation within the biotechnology industry, driven by its clinical progress and focus on addressing unmet medical needs in serious and rare diseases. Positive topline data from its pivotal Phase 3 clinical trials for veligrotug in TED have built confidence in its therapeutic approach and potential efficacy. The company's strategic positioning to leverage its innovative product pipeline and the positive analyst sentiment further contribute to its strong standing. The Breakthrough Therapy Designation for veligrotug also enhances its reputation.

Institutional ownership of Viridian Therapeutics is high, reported at 115.79% in October 2025 and 118.07% in July 2025. Fairmount Funds Management LLC purchased 454,545 shares of the company's stock for approximately $9,999,990 on October 23, 2025.